1 / 3

Immuno-Oncology Drugs Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026

Immuno-Oncology refers to the use of the body’s natural defences to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. I

RUSHIKESH
Download Presentation

Immuno-Oncology Drugs Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immuno-Oncology Drugs Market Set to Gain Traction over the Forecast Period 2018-2026 Immuno-oncology Drugs Market, by Drug Type , by Cancer Type , and by Region - Global Trends, and Forecast till 2025 Immuno-Oncology Drugs Market Immuno-Oncology refers to the use of the body’s natural defences to fght disease. It works by stimulating the immune system instead of fghting the tumors, avoiding disturbance in functionality of healthy cells. It helps the immune system to recognize and target cancer cells. The therapy facilitates long term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology therapy works against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses diferent types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classifed into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecifc monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

  2. Download PDF Brochure of Market Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1271 Active research and development by leading players as well as small innovative organizations are expected to boost growth of the immune-oncology drugs market According to the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015. Owing to benefts associated with these therapies, the leading players are actively investing in research and development into this treatment category through various collaborations and individual research studies. For instance, EMD Serono is involved in research and development of immune-oncology drugs and has a few drugs in pipeline such as M7824 (investigational) bifunctional immunotherapy. In 2015, Merck & Co., a leading drug manufacturer and MD Anderson Cancer Center entered into a strategic clinical research collaboration for formers drug Keytruda (Pembrolizumab). Celsee Diagnostics and IncellDx announced an immuno-oncology research agreement in 2017. Bristol-Myers Squibb is developing immuno-oncology approaches for treatment of colorectal cancer, lung cancer, melanoma, liver cancer, lymphoma, multiple myeloma, and others. Amgen, Inc. is actively involved in immune-oncology research and the company launched an immunotherapy collaboration with Kite Pharma to develop and commercialize chimeric antigen receptor (CAR) T cells in 2015. However, high cost of immuno-oncology therapies, which is unafordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Some major players operating in the immuno-oncology drugs market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hofmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfzer Inc., Sanof S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics &

  3. Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte. Browse more about the Deep Brain Stimulation Devices Market Study: https://www.coherentmarketinsights.com/insight/request-customization/1271 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting frm ofering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related